Literature DB >> 7205063

Congenital erythropoietic porphyria (Günther's disease): enzymatic studies on two cases of late onset.

J C Deybach, H de Verneuil, N Phung, Y Nordmann, A Puissant, B Boffety.   

Abstract

Cosynthetase was measured in hemolysates of two patients with CEP that appeared in adulthood. The level of cosynthetase activity was found to be very low (mean 18% of normal), ruling out the hypothesis of heterozygous cases. Several obligatory heterozygous carrier were also studied in whom cosynthetase activity was found to be intermediate (mean 46.66% of normal) between the levels of normal controls and homozygous patients whereas PBG deaminase was always normal. The nature of the metabolic abnormality is undoubtedly a primary defect of the cosynthetase activity; some cases of late onset emphasize the heterogeneity of the disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7205063

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  15 in total

1.  A novel point mutation in congenital erythropoietic porphyria in two members of Japanese family.

Authors:  K Tanigawa; M Bensidhoum; N Takamura; H Namba; S Yamashita; H de Verneuil; C Ged
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

2.  The molecular defect of ferrochelatase in a patient with erythropoietic protoporphyria.

Authors:  Y Nakahashi; H Fujita; S Taketani; N Ishida; A Kappas; S Sassa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

3.  Congenital erythropoietic porphyria and congenital adrenal hyperplasia with evidence for hepatic delta-5 alpha-reductase deficiency.

Authors:  J A Miller; G M Levene
Journal:  J R Soc Med       Date:  1989-02       Impact factor: 5.344

4.  Radiological features in congenital erythropoietic porphyria (Gunther's disease). Report of 3 cases.

Authors:  M Levesque; P Legmann; A Le Cloirec; J C Deybach; Y Nordmann
Journal:  Pediatr Radiol       Date:  1988

5.  Gene transfer of the uroporphyrinogen III synthase cDNA into haematopoietic progenitor cells in view of a future gene therapy in congenital erythropoietic porphyria.

Authors:  F Mazurier; F Moreau-Gaudry; S Salesse; C Barbot; C Ged; J Reiffers; H de Verneuil
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

6.  Simultaneous determination of hydroxymethylbilane synthase and uroporphyrinogen III synthase in erythrocytes by high-performance liquid chromatography.

Authors:  D J Wright; C K Lim
Journal:  Biochem J       Date:  1983-07-01       Impact factor: 3.857

7.  Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria.

Authors:  C Solis; G I Aizencang; K H Astrin; D F Bishop; R J Desnick
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 8.  Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Authors:  Vaithamanithi-Mudumbai Sadagopa Ramanujam; Karl Elmo Anderson
Journal:  Curr Protoc Hum Genet       Date:  2015-07-01

Review 9.  Porphyrias: animal models and prospects for cellular and gene therapy.

Authors:  H de Verneuil; C Ged; S Boulechfar; F Moreau-Gaudry
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

10.  Ocular involvement in two symptomatic congenital erythropoietic porphyria.

Authors:  F Oguz; M Sidal; C Bayram; N Sansoy; N Hekim
Journal:  Eur J Pediatr       Date:  1993-08       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.